Brought to you by 
Aslan brings in $34mm through Series C round; adds $9mm more
07 Jan 2016
Executive Summary
Immunotherapies developer Aslan Pharmaceuticals Pte. Ltd. raised $34mm through its Series C round. Accuron Technologies (a division of Temasek Holdings) led and was joined by other new investors Tianda Pharmaceuticals and Haitong International, along with returning backers Morningside, Bioveda (BVCF), Cenova, and Sagamore Bioventures.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Aslan brings in $34mm through Series C round; adds $9mm more
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice